Process Flow Controllers
Medchemexpress LLC Ars-853 | 1629268-00-3 | 98.39% | 432.94 | 1 ML
ARS-853 is a cell-active, selective, covalent KRAS G12C inhibitor with an IC50 of 2.5 μM. It inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation.
- Cell-active, selective, covalent KRAS G12C inhibitor.
- IC50 of 2.5 μM for KRAS(G12C).
- Inhibits mutant KRAS-driven signaling.
- Reduces GTP-bound KRAS levels by more than 95% at 10 μM in KRASG12C-mutant lung cancer cells.
- Inhibits proliferation with an IC50 similar to its target inhibition IC50.
- Selectively reduces KRAS-GTP levels and RAS-effector signaling in KRASG12C-mutant cells.
- Induces apoptosis in four KRASG12C mutant cell lines.
Selleck Chemical LLC ARS-1323-E1856-100MG
ARS-1323 is the racemic mixture containing ARS-1620 and a potent inhibitor of mutant KRAS G12C It can be used in research for biochemical binding screens as companion imaging drugs (CID) for KRAS G12C
Bertin Corp Coriolis Compact air sampler Civil security
Coriolis Compact air sampler Civil security including: 1 Coriolis Compact, 1 Coriolis Compact charger, 20 Cones (included air intake), 1 Shoulder strap, Ruggedized Transport box
Bertin Corp Coriolis Compact air sampler
Coriolis Compact air sampler Including :1 Coriolis Compact, 1 Coriolis Compact charger, 10 cones (included air intake), Standard Transport box
Medchemexpress LLC ARS-853 | 1629268-00-3 | 98.39% | 432.94 | 500 MG
ARS-853 is a cell-active, selective, covalent KRAS G12C inhibitor. It inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein, thereby preventing its activation. This compound is intended for research use only.
- Cell-active and selective KRAS G12C inhibitor.
- Inhibits mutant KRAS-driven signaling.
- Prevents activation of GDP-bound oncoprotein.
- Reduces GTP-bound KRAS levels by more than 95% at 10 μM in KRASG12C-mutant lung cancer cells.
- Inhibits proliferation, effector signaling, and induces apoptosis in KRASG12C mutant cell lines.
Sigma Aldrich Fine Chemicals Biosciences DDC Mass Spect GoldR Serum1L
DDC Mass Spect Gold is processed from human plasma using a validated process that reduces the hormone and steroid levels please see average hormone and steroid values below. This process also maintains the inherent characteristics of the human plasma resulting a in a pool that is consistent with patient samples. The human plasma is collected from donors at fDA licensed facilities. Each donor is screened for donor eligibility according to fDA regulations. Each unit is tested for and found negative for HIV1/2-ab HBsAg HCV-ab HIV-1 (NAT) HCV (NAT) and RPR. The plasma is inspected for conformance to raw material specifications. The plasma is processed according to a batch record. The finished product is analyzed and inspected according to quality control procedures for conformance to specifications. Records from donor unit(s) to final product are maintained according to established procedures. These records include donor records raw material inspection records batch records testing
